Vietnam Veterans Liver Fluke Cancer Study Act
Key claim: The bill requires the Department of Veterans Affairs to conduct an epidemiological study comparing cholangiocarcinoma incidence in Vietnam theater veterans versus U.S. residents, track prevalence via the VA Central Cancer Registry, and report findings periodically to Congress.
Abstract
(HR586 · 119th Congress) Vietnam Veterans Liver Fluke Cancer Study Act This bill requires the Department of Veterans Affairs (VA) to conduct an epidemiological study and report on the prevalence of cholangiocarcinoma (bile duct cancer) in veterans who served in the Vietnam theater of operations during the Vietnam era. The study must identify the rate of incidence of cholangiocarcinoma in such veterans and in U.S. residents. The bill also requires the VA to track and report on the prevalence of cholangiocarcinoma using the Veterans Affairs Central Cancer Registry. Additionally, the VA must periodically submit follow-up reports to Congress regarding the epidemiological study and information collected from the cancer registry regarding the prevalence of bile duct cancer. Latest action (2025-04-08): Received in the Senate and Read twice and referred to the Committee on Veterans’ Affairs.
Why this matters
If enacted, the bill would formalize VA epidemiological tracking of cholangiocarcinoma—a rare bile-duct cancer linked to liver fluke infection from freshwater fish consumed during Vietnam service—potentially strengthening the evidentiary base for future service-connection or presumptive disability determinations. For Vietnam-era veterans and their providers, systematic registry data could shift how VA screens, diagnoses, and adjudicates claims for this cancer. The bill itself only mandates study and reporting; it does not by itself change coverage or benefits.